6.42 USD
-0.1 (-1.53%)
At close: Jan 30, 2026
6.42 USD
0 (0%)
After Hours: 1/30/2026, 8:00:01 PM
Taking everything into account, BCYC scores 4 out of 10 in our fundamental rating. BCYC was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BCYC as it has an excellent financial health rating, but there are worries on the profitability. BCYC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year BCYC has reported negative net income.
- In the past year BCYC has reported a negative cash flow from operations.
- In the past 5 years BCYC always reported negative net income.
- In the past 5 years BCYC always reported negative operating cash flow.
1.2 Ratios
- BCYC's Return On Assets of -32.81% is fine compared to the rest of the industry. BCYC outperforms 64.38% of its industry peers.
- Looking at the Return On Equity, with a value of -40.53%, BCYC is in the better half of the industry, outperforming 70.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.81% | ||
| ROE | -40.53% | ||
| ROIC | N/A |
ROA(3y)-25.15%
ROA(5y)-24.21%
ROE(3y)-37.21%
ROE(5y)-36.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for BCYC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- BCYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, BCYC has more shares outstanding
- BCYC has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for BCYC has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 0.06, we must say that BCYC is in the distress zone and has some risk of bankruptcy.
- With a decent Altman-Z score value of 0.06, BCYC is doing good in the industry, outperforming 61.33% of the companies in the same industry.
- BCYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.06 |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
- A Current Ratio of 10.66 indicates that BCYC has no problem at all paying its short term obligations.
- BCYC has a Current ratio of 10.66. This is amongst the best in the industry. BCYC outperforms 83.43% of its industry peers.
- BCYC has a Quick Ratio of 10.66. This indicates that BCYC is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of BCYC (10.66) is better than 83.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.66 | ||
| Quick Ratio | 10.66 |
3. Growth
3.1 Past
- BCYC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.16%.
- BCYC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.20%.
- BCYC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.65% yearly.
EPS 1Y (TTM)-12.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.86%
Revenue 1Y (TTM)-23.2%
Revenue growth 3Y44.46%
Revenue growth 5Y20.65%
Sales Q2Q%338.49%
3.2 Future
- The Earnings Per Share is expected to grow by 8.28% on average over the next years. This is quite good.
- Based on estimates for the next years, BCYC will show a very strong growth in Revenue. The Revenue will grow by 54.47% on average per year.
EPS Next Y-33.25%
EPS Next 2Y-14%
EPS Next 3Y-6.96%
EPS Next 5Y8.28%
Revenue Next Year-13.15%
Revenue Next 2Y-9.09%
Revenue Next 3Y9.51%
Revenue Next 5Y54.47%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for BCYC. In the last year negative earnings were reported.
- Also next year BCYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as BCYC's earnings are expected to decrease with -6.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14%
EPS Next 3Y-6.96%
5. Dividend
5.1 Amount
- BCYC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BICYCLE THERAPEUTICS PLC-ADR / BCYC FAQ
What is the fundamental rating for BCYC stock?
ChartMill assigns a fundamental rating of 4 / 10 to BCYC.
Can you provide the valuation status for BICYCLE THERAPEUTICS PLC-ADR?
ChartMill assigns a valuation rating of 0 / 10 to BICYCLE THERAPEUTICS PLC-ADR (BCYC). This can be considered as Overvalued.
What is the profitability of BCYC stock?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) has a profitability rating of 1 / 10.
How financially healthy is BICYCLE THERAPEUTICS PLC-ADR?
The financial health rating of BICYCLE THERAPEUTICS PLC-ADR (BCYC) is 7 / 10.
What is the expected EPS growth for BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?
The Earnings per Share (EPS) of BICYCLE THERAPEUTICS PLC-ADR (BCYC) is expected to decline by -33.25% in the next year.